Gene · 3817
Papers1,753
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,753
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. | Ther Adv Urol | 2023 | 37359737 | PubTator, text mining | PubMed |
| Minor intron splicing is critical for survival of lethal prostate cancer. | Mol Cell | 2023 | 37295433 | PubTator, text mining | PubMed |
| Development and nationwide validation of kidney graft injury markers using urinary exosomes and microvesicles (complete English translation of the Japanese version). | BMC Nephrol | 2023 | 37280521 | PubTator, text mining | PubMed |
| Characterisation of cell lines derived from prostate cancer patients with localised disease. | Prostate Cancer Prostatic Dis | 2023 | 37264224 | PubTator, text mining | PubMed |
| Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells. | Front Immunol | 2023 | 37261346 | PubTator, text mining | PubMed |
| Aryl Hydrocarbon Receptor as an Anticancer Target: An Overview of Ten Years Odyssey. | Molecules | 2023 | 37241719 | PubTator, text mining | PubMed |
| SERS Immunosensors for Cancer Markers Detection. | Materials (Basel) | 2023 | 37241360 | PubTator, text mining | PubMed |
| Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer. | Int J Mol Sci | 2023 | 37240349 | PubTator, text mining | PubMed |
| Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer. | Int J Mol Sci | 2023 | 37240308 | PubTator, text mining | PubMed |
| Advances, Limitations and Future Challenges in the Management of Immunotherapy for Hematological Diseases and Solid Tumors. | Int J Mol Sci | 2023 | 37240158 | PubTator, text mining | PubMed |
| Quercetin can be a more reliable treatment for metastatic prostate cancer than the localized disease: An in vitro study. | J Cell Mol Med | 2023 | 37232542 | PubTator, text mining | PubMed |
| Towards Understanding the Key Signature Pathways Associated from Differentially Expressed Gene Analysis in an Indian Prostate Cancer Cohort. | Diseases | 2023 | 37218885 | PubTator, text mining | PubMed |
| Natural flavonols: actions, mechanisms, and potential therapeutic utility for various diseases. | Beni Suef Univ J Basic Appl Sci | 2023 | 37216013 | PubTator, text mining | PubMed |
| Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy. | World J Urol | 2023 | 37209144 | PubTator, text mining | PubMed |
| Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for Prostate-Specific Antigen Levels in Men Without Prostate Cancer. | medRxiv | 2023 | 37205487 | PubTator, text mining | PubMed |
| New insights into lipid metabolism and prostate cancer (Review). | Int J Oncol | 2023 | 37203395 | PubTator, text mining | PubMed |
| AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer. | Front Oncol | 2023 | 37197416 | PubTator, text mining | PubMed |
| Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment. | Cancers (Basel) | 2023 | 37190171 | PubTator, text mining | PubMed |
| Natural compounds ursolic acid and digoxin exhibit inhibitory activities to cancer cells in RORγ-dependent and -independent manner. | Front Pharmacol | 2023 | 37180705 | PubTator, text mining | PubMed |
| Kallikrein-Related Peptidase 12 (KLK12) in Breast Cancer as a Favorable Prognostic Marker. | Int J Mol Sci | 2023 | 37176127 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3817/papers?page=7